Clinical trials: Camrelizumab
Rectal Cancer, Radiotherapy
Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal Cancer
This is a open-label, single-arm study to investigate the safety and efficacy of consolidative chemotherapy with camrelizumab, an anti-PD-1 antibody drug following short course radiotherapy and subsequent surgical therapy in…
- Conditions
- Rectal Cancer, Radiotherapy, Immunotherapy
- Trial name
- NCT04231552
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Cervical Cancer, Immunochemotherapy
Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial
Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.
- Trial name
- NCT07167160
- Testing
- Camrelizumab combined with chemotherapy
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Women's Hospital School Of Medicine Zhejiang University
Carcinoma, Cervix Carcinoma
Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin
This study is a single arm, exploratory clinical study aimed at evaluating the efficacy and safety of karelizumab combined with etoposide and cisplatin in the neoadjuvant treatment of neuroendocrine cervix carcinoma.
- Trial name
- NCT05910177
- Testing
- Karelizumab combined with etoposide and cisplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fujian Cancer Hospital
Oligometastatic Disease
Consolidative Radiotherapy Combined With Camrelizumab and Chemotherapy for Oligometastatic Nasopharyngeal Carcinoma
The purpose of this study is to explore the efficacy and tolerance of local consolidative radiotherapy combined with Camrelizumab and chemotherapy in patients with oligometastatic nasopharyngeal carcinoma
- Trial name
- NPC-CR01 (NCT05128201)
- Testing
- consolidative radiotherapy
- Where
- 3 sites in China
- Volunteers
- 63 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Malignant Pleural Effusion
A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion
Patients with a variety of malignancies can develop malignant pleural effusion (MPE). MPE can cause significant symptoms and result in a marked decrease in quality of life and a poor prognosis.
- Trial name
- NCT05330065
- Testing
- bevacizumab and camrelizumab
- Volunteers
- 55 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Classical Hodgkin Lymphoma
Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma
This is a prospective single-arm, multi-center and phase II clinical trial to observe the efficacy and safety of Camrelizumab combined with AVD in the first-line treatment for patients with advanced classical Hodgkin's lymphoma.
- Trial name
- NCT04067037
- Testing
- Camrelizumab, Epirubicin, Vincristine
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital
Breast Neoplasms
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
RATIONALE: Patients with HER2-negative advanced breast cancer have limited choice on targeted therapies, and often show only modest responses to available immunotherapies.
- Trial name
- NCT05981001
- Testing
- Surgery for harvesting tumor-draining lymph nodes, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Gastric Cancer, HIPEC, Anti-PD-1 Antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery
HIPEC Combined With Camrelizumab, Paclitaxel and S-1 for Conversion Therapy in Patients With Advanced Gastric Cancer With Peritoneal Metastasis
There is no currently available treatment for peritoneal metastasis of gastric cancer. Hyperthermic intraperitoneal chemotherapy (HIPEC) can not only maintain the high concentration of drugs in the abdominal cavity, but also…
- Trial name
- NCT04889768
- Testing
- HIPEC, anti-PD-1 antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Zhejiang Cancer Hospital
Gastric Cancer Stage III
Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)
This study is a prospective, single arm, multi-center phase II clinical trial. The primary study objective is to evaluate the safety of tegafur gimeracil oteracil potassium capsule plus oxaliplatin and Camrelizumab as adjuvant…
- Trial name
- NCT04515615
- Testing
- Camrelizumab, Oxaliplatin, Tegafur gimeracil oteracil potassium capsule
- Where
- 4 sites in China
- Volunteers
- 52 people
- Sponsor
- Yu jiren
Advanced Solid Tumor
A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor
It is a single-arm, open-label, multicenter, phase I trial,aiming at exploring the MTD and RP2D of Linperlisib combination with Camrelizumab in treating patients with advanced solid tumor,observing the preliminary efficacy.
- Trial name
- NCT05429398
- Testing
- Linperlisib Tablet
- Volunteers
- 118 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
Gastric Cancer
Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
This is a study of Camrelizumab in Combination With concurrent radiotherapy and SOX for Initial Unresectable or potentially resectable proximal Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
- Trial name
- NCT04631757
- Testing
- Camrelizumab + SOX + Radiotherapy
- Volunteers
- 33 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
BCLC Stage C Hepatocellular Carcinoma, Chemotherapy Effect
Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC
This is a multi-center randomized phase III clinical study of first-line intravenous FOLFOX plus Camrelizumab and apatinib versus HAIC-FOLFOX plus Camrelizumab and apatinib for BCLC C stage hepatocellular carcinoma.
- Trial name
- NCT06172205
- Testing
- intravenous FOLFOX7 plus Camrelizumab and apatinib, HAIC-FOLFOX plus Camrelizumab and apatinib
- Where
- China
- Volunteers
- 262 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Primary Hepatocellular Carcinoma
Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma
VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 injection.This study will be conducted in combination with camrelizumab in patients with advanced advanced primary hepatocellular carcinoma who have received at least one…
- Trial name
- NCT06124001
- Testing
- Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), camrelizumab for Injection
- Volunteers
- 36 people
- Sponsor
- CNBG-Virogin Biotech (Shanghai) Ltd.
Stage IV Gastric Cancer With Metastasis
Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis：Single-arm, Prospective Clinical Study
The purpose of this study was to evaluate the efficacy of camrelizumab combined with nab-paclitaxel intraperitoneal infusion, intravenous chemotherapy and S-1 in the treatment of advanced gastric cancer with peritoneal…
- Trial name
- NCT05441254
- Testing
- Camrelizumab; Nab-paclitaxel; S-1
- Volunteers
- 33 people
- Sponsor
- Zhongshan Hospital Xiamen University
Sarcoma
A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS
This study is a Single-arm, Open, Prospective, Single-center, Phase Ⅱ Clinical Study ,Target population is Advanced Inoperable Resection of Undifferentiated Pleomorphic Sarcoma (UPS) and Alveolar Soft Tissue Sarcoma (ASPS) .
- Trial name
- NCT04447274
- Testing
- Camrelizumab and Apatinib
- Volunteers
- 20 people
- Sponsor
- Chinese Academy of Medical Sciences
Early Stage Non-small Cell Lung Cancer
Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC
The purpose of this study is to assess the efficacy and safety of Camrelizumab plus chemotherapy in the treatment of adult participants with medically inoperable Stage I or IIA non-small cell lung cancer (NSCLC).
- Trial name
- NCT04530227
- Testing
- Biological: Camrelizumab, Pemetrexed, Nab-paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Cervical Cancer, Locally Advanced Cervical Cancer
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
This is a multicenter, prospective, single-arm, phase 2 clinical trial designed to evaluate the therapeutic efficacy of the NACI (neoadjuvant chemotherapy plus Camrelizumab) for PD-L1-negative locally advanced cervical cancer.
- Conditions
- Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative, Neoadjuvant Chemoimmunotherapy
- Trial name
- NCT06288360
- Testing
- Camrelizumab, Paclitaxel-albumin, Cisplatin
- Where
- 12 sites in China
- Volunteers
- 40 people
- Sponsor
- Tongji Hospital
BRCA-Mutated Breast Carcinoma, HER2-negative Breast Cancer
Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab
This study is a prospective, open-label, multi-center, phase II clinical trial designed for HER2-negative breast cancer with pathogenic mutations in the germline gene (gBRCA1/2) that were indicated for neoadjuvant chemotherapy.
- Trial name
- NCT06516289
- Testing
- HRS-1167, Famitinib, Camrelizumab
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Fudan University
Advanced Hepatocellular Carcinoma
Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma
This is a prospective, single-arm, phase Ib/II trial . The objective of this study is to evaluate the efficacy and safety of adebrelimab, camrelizumab plus apatinib as first-line therapy in patients with advanced hepatocellular…
- Trial name
- NCT05924997
- Testing
- adebrelimab, camrelizumab plus apatinib
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma
Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure
This is a prospective phase II clinical trial to evaluate the efficacy and safety of apatinib and camrelizumab in recurrent or metastatic nasopharyngeal carcinoma who failed at least the first-line treatment.
- Conditions
- Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma, Chemotherapy Effect
- Trial name
- NCT04586088
- Testing
- Apatinib plus Camrelizumab
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Sun Yat-sen University